Foresee Pharmaceuticals Co., Ltd. announced the appointment of two key executives with strong medical, scientific and drug development experience and expertise, solidifying Foresee's position as it embarks on a path towards significant milestones: Dr. Yisheng Lee in the role of Chief Medical Officer; and Dr. David Lau in the role of Senior Vice President, NCE Preclinical and Clinical Development. Dr. Yisheng Lee will play a leading role in establishing Foresee's strategies related to portfolio management, clinical trials, regulatory affairs, pharmacovigilance and risk management. With his broad experience in clinical practice, medical education, and academic research, Dr. Lee will play a leading role in continuing to enhance Foresee's network with academic institutions and clinical trial sites. Dr. David Lau will lead Foresee's NCE preclinical and clinical development, including pharmacokinetics, drug metabolism, bioanalysis, toxicology, and preclinical/clinical pharmacology. Dr. Lau will also play a strategic role in the scientific support related to the out-licensing/partnering of Foresee's programs and in the evaluation and selection of any new drug in-licensing opportunities.